Invesco DB Precious Metals Fund filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss for the nine-month period alongside a decline in shares outstanding and total shareholders' equity.
Fluor Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting third-quarter revenue of $3.72 billion and a return to operating profit after a substantial loss in the year-earlier quarter.
Moelis & Company filed its Form 10-Q with the SEC on November 6, 2026, covering the quarterly period ended September 30, 2026, reporting third-quarter revenues of $425,577 thousand and net income attributable to the company of $58,656 thousand.
Invesco DB Oil Fund filed its Form 10-Q with the SEC on November 6, 2026, covering the quarterly period ended September 30, 2026, and reporting net income of $74,035,471 for the three months ended on that date.
Invesco DB Energy Fund filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, disclosing financial results and portfolio positions for the three and nine months ended on that date.
Invesco DB Base Metals Fund filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting total shareholders' equity of $344,022,894 and a net asset value per share of $25.30.
Invesco CurrencyShares British Pound Sterling Trust (NYSE Arca:FXB) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting total assets of $89,505,284 and 700,000 redeemable capital shares outstanding.
Invesco CurrencyShares Japanese Yen Trust filed its Form 10-Q for the quarterly period ended September 30, 2026, disclosing unaudited financial results and balance sheet data for the trust listed on NYSE Arca under the symbol FXY.
Invesco CurrencyShares Australian Dollar Trust filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 6, 2026, reporting financial results and balance sheet data for the third quarter.
Starling Oncology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting total operating revenue of $169.8 million for the third quarter and a net loss of $15.7 million.